扬子江药业集团经营创新力持续提升

Core Insights - Yangtze River Pharmaceutical Group has shown continuous improvement in operational innovation during the first half of 2023, despite a challenging external environment [1][2] - The company is focusing on a "health ecosystem" strategy and has achieved significant milestones in management, innovation, and corporate governance [1] Group 1: Operational Performance - In the first half of 2023, Yangtze River achieved a seven-star certification in the EFQM global award's first phase, making it the only pharmaceutical company in China to do so [1] - The company was recognized as one of the first batch of excellent intelligent factories in the country, indicating its advanced level in smart manufacturing [1] - The innovative traditional Chinese medicine product, Yiqi Tongqiao Wan, was launched nationwide, marking a significant achievement in treating allergic rhinitis [1] Group 2: Strategic Initiatives - The company is committed to the "health marketing" philosophy and is actively participating in national health initiatives, including the "Weight Management Year" campaign [2] - Yangtze River hosted its first Health Culture Festival and established the "Yangtze River Cultural Salon" to promote health culture [2] - The company has organized over 3,700 offline health activities as part of its "All Staff Sports Day" initiative [2] Group 3: Growth and Future Plans - The health sector and international business of Yangtze River have seen substantial growth, with year-on-year increases of 365% and 237%, respectively [2] - The company aims to prepare for the second phase of the EFQM global award assessment and is focusing on high-quality research and development projects [2] - Yangtze River is also exploring the application of AI in the acceptance of medicinal materials and is implementing 52 energy-saving and emission-reduction projects [2]